Enzyme immunoassay for the quantitative determination (screening) of antibodies to Nivolumab (Opdivo®) in serum and plasma with confirmation.
This kit has been especially developed for the quantitative determination of antibodies to nivolumab in serum and plasma samples.
Nivolumab (Opdivo®) was associated to the development of anti-Nivolumab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Opdivo®. This might lead to severe complications. This kit can be efficiently used for monitoring anti-Nivolumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Nivolumab antibodies.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact firstname.lastname@example.org
|Required Volume (µl)||20|
|Total Time (min)||140|
|Detection Limit (ng/mL)||7,5|
|Spike Recovery (%)||Between 85-115|
|Shelf Life (year)||1|
|Storage conditions||Store at +4°C. Please refer to protocols.|
|Shipping conditions||At room temperature|
|Instructions For Use||Download|
|Safety Data Sheet (SDS)||Download|
Publications with this drug
|Sureda, Manuel, et al. "Therapeutic drug monitoring of nivolumab in routine clinical practice. A pilot study." Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 44.3 (2020): 81-86.||Visit Link|
|Nieto, Juan C., et al. "Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy." Leukemia (2020): 1-6.||Visit Link|
|Abe, Kazuki, et al. "Quantitative LC-MS/MS method for nivolumab in human serum using IgG purification and immobilized tryptic digestion." Analytical Methods 12.1 (2020): 54-62.||Visit Link|
|Sureda, Manuel, et al. "Therapeutic drug monitoring of nivolumab in clinical practice: Preliminary experience." DEVELOPMENTAL IMMUNOTHERAPY AND TUMOR IMMUNOBIOLOGY (2019)||Visit Link|
|García Gil S, Ramos Díaz R., ANÁLISIS DE LA CONCENTRACIONES PLASMÁTICAS DE NIVOLUMAB EN EL TRATAMIENTO DEL CPNM||Visit Link|